Corbus Pharmaceuticals Holdings Inc Stock

$7.40

7.73% yesterday

Nasdaq, Jun 27, 10:16 pm CET

ISIN

US21833P1030

Symbol

CRBP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Corbus Pharmaceuticals Holdings Inc Stock price

$7.40

-229.90 96.88% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.62 7.73%

ISIN

US21833P1030

Symbol

CRBP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$90.6m

Enterprise Value

$-42.2m

Net debt

$-132.8m

Cash

$132.8m

Shares outstanding

12.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | 62.15

EV/Sales

- | negative

EV/FCF

0.84

P/B

0.70

Financial Health

Equity Ratio

91.03%

Return on Equity

-28.17%

ROCE

-46.88%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $1.5m

EBITDA

$-59.5m | -

EBIT

$-60.0m

Net Income

$-50.5m | $-75.0m

Free Cash Flow

$-50.0m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

-61.67% | -

EBIT

-60.41%

Net Income

-49.72% | -87.55%

Free Cash Flow

-72.76%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -5,148.77%

Free Cash Flow

EPS

$-4.22

FCF per Share

$-4.17

Short interest

19.03%

Employees

28.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Corbus Pharmaceuticals Holdings Inc Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

15x Buy

94%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Corbus Pharmaceuticals Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	17 17	21% 21% -
- Research and Development Expense	42 42	79% 79% -
EBITDA	-59 -59	62% 62% -
- Depreciation and Amortization	0.52 0.52	15% 15% -
EBIT (Operating Income) EBIT	-60 -60	60% 60% -
Net Profit	-51 -51	50% 50% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Corbus Pharmaceuticals Holdings Inc Stock News

Neutral

GlobeNewsWire

●

3 days ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study a...

Neutral

GlobeNewsWire

●

4 days ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fire side chat at the Piper Sandler 3rd Annual Virtual Obesity Symposium, to be held on June 26, 2025. The event will include presentations by key opinion leaders and ...

Neutral

Seeking Alpha

●

11 days ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

CRBP's pipeline shows promise, especially CRB-701 with early signals of benefit and tolerability, but all programs remain in early clinical stages. The company's financial position is stable for now, with about two years of cash runway, but rising R&D costs could accelerate the need for funding. Market sentiment has become overly negative, valuing the pipeline at essentially zero after a steep ...

More Corbus Pharmaceuticals Holdings Inc News

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Head office	United States
CEO	Yuval Cohen
Employees	28
Founded	2009
Website	www.corbuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now